STOCK TITAN
  1. Home
  2. News
  3. GERN

Geron Corp. - GERN STOCK NEWS

Welcome to our dedicated news page for Geron (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Geron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Geron's position in the market.

News
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
Rhea-AI Summary
Geron (Nasdaq: GERN) will announce its first quarter 2024 financial results and business highlights on May 2, 2024. The company will host a conference call to discuss the results and highlights at 8:00 a.m. ET the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Geron (GERN) reported granting non-statutory stock options to purchase 243,000 shares of Geron common stock as inducements to newly hired employees. The options were granted at an exercise price of $3.68 per share and have a 10-year term, vesting over four years. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
News
Geron to Participate at Upcoming Investor Conferences in April
Rhea-AI Summary
Geron (GERN) announces CEO's participation in upcoming virtual investor conferences. John A. Scarlett, M.D., to present at Needham Virtual Healthcare Conference and Stifel's Targeted Oncology Days. Webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
Geron (GERN) announces the pricing of an underwritten offering of common stock and pre-funded warrants. The offering includes 41,999,998 shares at $3.00 per share and pre-funded warrants for 8,002,668 shares at $2.999 per warrant. The offering involves various investment firms and is set to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
offering
-
News
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
Rhea-AI Summary
Geron Corporation's imetelstat receives positive vote from FDA Oncologic Drugs Advisory Committee for the treatment of transfusion-dependent anemia in adult patients with LR-MDS. The IMerge Phase 3 trial results show significant clinical benefit with improved red blood cell transfusion independence and hemoglobin levels. The PDUFA target action date is set for June 16, 2024, indicating a potential new treatment option for patients with unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Geron Corporation reported business highlights and financial results for 2023, focusing on the potential FDA approval of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS. The company achieved significant milestones in clinical trials and regulatory approvals, positioning itself for a commercial launch in the U.S. and EU. Financially, Geron projects sufficient funding into Q3 2025, with a focus on increasing headcount and commercial preparations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
earnings
News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Geron Corporation (GERN) grants non-statutory stock options to newly hired employees as inducements. The options total 397,010 shares at $1.93 per share, with vesting terms over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
News
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Rhea-AI Summary
Geron Corporation (GERN) will release its Q4 and full-year 2023 financial results and business highlights on February 28, 2024. The company will host a conference call to discuss the results and a live webcast will be available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
earnings
-
News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Geron Corporation (GERN) has granted non-statutory stock options to newly hired employees, totaling 895,930 shares, with an exercise price of $1.92 per share. The options have a 10-year term, vesting over four years, and were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
News
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
Rhea-AI Summary
Geron Corporation (GERN) CEO to participate in fireside chat at B. Riley Securities Virtual Oncology Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
Stock GERN logo
Geron Corp.

Nasdaq:GERN

GERN Rankings

#1833 Ranked by Market Cap
#3292 Ranked by Stock Gains
N/A Ranked by Dividends

GERN Stock Data

2.14B
475.07M
0.09%
67.83%
7.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Foster City

About GERN

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.